GNI Group Ltd. (FRA:3G6)

Market Cap	702.62M
Revenue (ttm)	148.45M
Net Income (ttm)	-4.74M
Shares Out	n/a
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	12.30
Previous Close	12.70
Day's Range	12.30 - 12.30
52-Week Range	8.80 - 26.00
Beta	n/a
RSI	42.77
Earnings Date	Feb 13, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 867
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3G6

Financial Performance

In 2024, GNI Group's revenue was 23.61 billion, a decrease of -9.22% compared to the previous year's 26.01 billion. Earnings were 1.10 billion, a decrease of -86.43%.

Financial numbers in JPY